{"id": "e2d489f9-22d1-4b57-9f7e-f7c8b34b42b3", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 0, "timestamp_utc": "2026-02-06T03:28:27.990712+00:00", "question": "What was the primary endpoint of the Phase 2 trial for Once-Daily Compound ZN-314?", "gold_answer": "Change in composite symptom score from baseline to week 12", "model_answer": "The primary endpoint of the Phase 2 trial for Once-Daily Compound ZN-314 was the change in composite symptom score from baseline to week 12.", "question_profile": {"topic": "life_science", "reasoning_type": "retrieval", "difficulty": 1, "task_type": "extractive_qa", "source_id": "sample_article", "claim_text": "", "expected_verdict": "NA", "utility_rationale": "This question tests the ability to directly retrieve specific information from the source.", "quality_risk": "none"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "cold_start"}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer is accurate and directly matches the information provided in the source context.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": false}}
{"id": "6e8c74c7-162f-43cb-991b-e0cf796b969c", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 1, "timestamp_utc": "2026-02-06T03:28:53.132360+00:00", "question": "What was the between-group difference in mean symptom score improvement at week 12 between the ZN-314 group and placebo?", "gold_answer": "-4.7 points", "model_answer": "The between-group difference in mean symptom score improvement at week 12 between the ZN-314 group and placebo was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).", "question_profile": {"topic": "life_science", "reasoning_type": "numerical reasoning", "difficulty": 1, "task_type": "extractive_qa", "source_id": "sample_article", "claim_text": "", "expected_verdict": "NA", "utility_rationale": "This question tests the ability to extract a specific numerical value directly from the source text.", "quality_risk": "none"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.1786, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question is asking about the between-group difference in mean symptom score improvement at week 12 between the ZN-314 group and placebo, which is different from the previous question that focused on the primary endpoint of the Phase 2 trial for Once-Daily Compound ZN-314."}}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer is accurate and directly extracted from the provided source content. The between-group difference in mean symptom score improvement at week 12 between the ZN-314 group and placebo was indeed -4.7 points.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": false}}
{"id": "129ad5d5-ccf8-44e9-8117-16af814efaa1", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 2, "timestamp_utc": "2026-02-06T03:29:01.490612+00:00", "question": "What was the between-group difference in mean symptom score improvement at week 12 between the subgroup with baseline CRP above 10 mg/L on ZN-314 and placebo?", "gold_answer": "Verdict: FAITHFUL. The between-group difference in mean symptom score improvement at week 12 between the subgroup with baseline CRP above 10 mg/L on ZN-314 and placebo was 6 points, as the text mentions a larger mean improvement of 9.1 points on ZN-314 compared to placebo.", "model_answer": "Verdict: NOT_MENTIONED\nInsufficient evidence is provided to determine the between-group difference in mean symptom score improvement at week 12 between the subgroup with baseline CRP above 10 mg/L on ZN-314 and placebo.", "question_profile": {"topic": "life_science", "reasoning_type": "retrieval", "difficulty": 3, "task_type": "claim_quality_check", "source_id": "sample_article", "claim_text": "", "expected_verdict": "FAITHFUL", "utility_rationale": "This question tests the ability to extract specific information about subgroup analysis and between-group differences, requiring understanding of the given data.", "quality_risk": "none"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.6667, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question introduces a new subgroup based on baseline CRP above 10 mg/L, which is not present in the previous questions. Therefore, it is considered novel."}}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer accurately reflects the information provided in the source context, where it is indeed not explicitly mentioned what the between-group difference in mean symptom score improvement at week 12 was between the subgroup with baseline CRP above 10 mg/L on ZN-314 and placebo. Therefore, the candidate answer is correct in stating that there is insufficient evidence to determine this difference.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": true}}
{"id": "d2174034-6fb6-40bb-8368-a895df9338b7", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 3, "timestamp_utc": "2026-02-06T03:29:07.030555+00:00", "question": "If the Phase 2 trial for Once-Daily Compound ZN-314 had enrolled 200 adults instead of 180, what would be the expected between-group difference in mean symptom score improvement at week 12 according to the data provided?", "gold_answer": "Verdict: HALLUCINATED. The expected between-group difference in mean symptom score improvement at week 12 cannot be directly inferred by scaling up the enrolled adults as the study results are specific to the actual sample size of 180 adults.", "model_answer": "Verdict: NOT_MENTIONED\nInsufficient evidence is provided to calculate the expected between-group difference in mean symptom score improvement if the Phase 2 trial had enrolled 200 adults instead of 180.", "question_profile": {"topic": "life_science", "reasoning_type": "counterfactual", "difficulty": 3, "task_type": "claim_quality_check", "source_id": "sample_article", "claim_text": "", "expected_verdict": "HALLUCINATED", "utility_rationale": "This question tests the understanding of how changing the sample size in a clinical trial impacts the interpretation of study results.", "quality_risk": "weak_gold"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.375, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question is asking about the expected between-group difference in mean symptom score improvement at week 12 for a different scenario in the Phase 2 trial of Once-Daily Compound ZN-314, which is not directly covered by any of the previous questions."}}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer correctly states that there is insufficient evidence provided in the source to calculate the expected between-group difference in mean symptom score improvement if the Phase 2 trial had enrolled 200 adults instead of 180. The gold answer is also accurate in stating that the expected between-group difference cannot be directly inferred by scaling up the enrolled adults due to the specific nature of the study results.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": true}}
{"id": "12d034b5-064a-43bd-9a20-90b09a7984ae", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 4, "timestamp_utc": "2026-02-06T03:29:17.114142+00:00", "question": "What was the mean improvement in symptom score at week 12 for the prespecified subgroup with baseline CRP above 10 mg/L on ZN-314?", "gold_answer": "Mean improvement of 9.1 points on ZN-314.", "model_answer": "The mean improvement in symptom score at week 12 for the prespecified subgroup with baseline CRP above 10 mg/L on ZN-314 was 9.1 points.", "question_profile": {"topic": "life_science", "reasoning_type": "retrieval", "difficulty": 3, "task_type": "extractive_qa", "source_id": "sample_article", "claim_text": "", "expected_verdict": "NA", "utility_rationale": "This question requires understanding the concept of a prespecified subgroup and identifying the specific mean improvement score within the same paragraph.", "quality_risk": "none"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.7586, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question is asking specifically about the mean improvement in symptom score at week 12 for the prespecified subgroup with baseline CRP above 10 mg/L on ZN-314, which is different from the previous questions that focus on between-group differences and primary endpoints."}}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer is accurate and directly supported by the information provided in the source context. The mean improvement in symptom score at week 12 for the prespecified subgroup with baseline CRP above 10 mg/L on ZN-314 was indeed 9.1 points.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": false}}
{"id": "743387e5-84af-41d8-bb90-baf4162b55c8", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 5, "timestamp_utc": "2026-02-06T03:29:23.510181+00:00", "question": "If the Phase 2 trial for Once-Daily Compound ZN-314 had lasted for 24 weeks instead of 12, what would be the expected difference in mean symptom score improvement between the ZN-314 group and placebo?", "gold_answer": "Verdict: The expected between-group difference in mean symptom score improvement at week 24 can be estimated by extrapolating the rate of improvement observed in the trial up to week 12. However, it would require additional data or assumptions to accurately predict the exact difference.", "model_answer": "Insufficient evidence to determine the expected difference in mean symptom score improvement between the ZN-314 group and placebo if the Phase 2 trial had lasted for 24 weeks instead of 12.", "question_profile": {"topic": "life_science", "reasoning_type": "counterfactual", "difficulty": 3, "task_type": "extractive_qa", "source_id": "sample_article", "claim_text": "", "expected_verdict": "NA", "utility_rationale": "This question tests the ability to extrapolate trial data and project outcomes under different conditions, which can be challenging due to the need for assumptions and understanding of the trial dynamics.", "quality_risk": "unsupported"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.6429, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question is asking about the expected difference in mean symptom score improvement between the ZN-314 group and placebo if the Phase 2 trial had lasted for 24 weeks instead of 12, which is different from the previous questions that focused on enrollment numbers, specific time points, primary endpoints, and subgroup analyses."}}, "evaluation": {"score": 0.7, "is_correct": false, "feedback": "The candidate answer correctly states that there is insufficient evidence to determine the expected difference in mean symptom score improvement between the ZN-314 group and placebo if the Phase 2 trial had lasted for 24 weeks instead of 12. However, it does not mention the possibility of extrapolating the rate of improvement observed in the trial up to week 12 to estimate the difference, which is a key point based on the provided context.", "error_type": "incorrect_information", "quality_flags": [], "ambiguity_note": "", "claim_verdict_match": false}}
{"id": "203feff9-8ddc-4ff9-9c67-dfef7ea927dc", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 6, "timestamp_utc": "2026-02-06T03:29:28.611016+00:00", "question": "If the Phase 2 trial for Once-Daily Compound ZN-314 had been extended to 16 weeks instead of 12, what would be the expected between-group difference in mean symptom score improvement according to the data provided?", "gold_answer": "Verdict: NOT_MENTIONED. The article does not provide information on the expected between-group difference in mean symptom score improvement at 16 weeks.", "model_answer": "Insufficient evidence is provided to determine the expected between-group difference in mean symptom score improvement if the Phase 2 trial for Once-Daily Compound ZN-314 had been extended to 16 weeks instead of 12.", "question_profile": {"topic": "life_science", "reasoning_type": "counterfactual", "difficulty": 1, "task_type": "abstractive_qa", "source_id": "sample_article", "claim_text": "", "expected_verdict": "NA", "utility_rationale": "This question tests the understanding of the information provided in the article and the ability to make inferences based on the trial duration extension.", "quality_risk": "unsupported"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.7561, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question is asking about the expected between-group difference in mean symptom score improvement for Once-Daily Compound ZN-314 at 16 weeks, which is different from the previous questions that focused on different scenarios (e.g., enrollment numbers, trial duration, subgroup analysis). Therefore, the candidate question is considered novel."}}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer accurately reflects the lack of information provided in the source regarding the expected between-group difference in mean symptom score improvement at 16 weeks. The source only mentions data up to week 12, so any speculation about the 16-week time point would be unsupported.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": false}}
{"id": "5a02d1b9-3524-41a3-a5d9-b4ce1acc257a", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 7, "timestamp_utc": "2026-02-06T03:29:33.951149+00:00", "question": "What was the ratio of participant assignment to ZN-314 50 mg once daily or placebo in the Phase 2 trial for Once-Daily Compound ZN-314?", "gold_answer": "2:1", "model_answer": "Participants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo in the Phase 2 trial for Once-Daily Compound ZN-314.", "question_profile": {"topic": "life_science", "reasoning_type": "retrieval", "difficulty": 1, "task_type": "abstractive_qa", "source_id": "sample_article", "claim_text": "", "expected_verdict": "NA", "utility_rationale": "This question tests the ability to retrieve a single-sentence fact from the source.", "quality_risk": "none"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.5417, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question is asking about the ratio of participant assignment to ZN-314 50 mg once daily or placebo in the Phase 2 trial for Once-Daily Compound ZN-314, which is different from all the previous questions that focused on endpoints, duration, enrollment numbers, and subgroup analysis."}}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer accurately reflects the information provided in the source context regarding the participant assignment ratio in the Phase 2 trial for Once-Daily Compound ZN-314.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": false}}
{"id": "3f61ecac-e541-4fcd-abc6-ae2415648f70", "run_id": "36cbef86-c393-4976-8ab3-54f533cfda99", "round_index": 8, "timestamp_utc": "2026-02-06T03:29:43.659086+00:00", "question": "What was the percentage of treatment-emergent adverse events in participants assigned to ZN-314 50 mg once daily in the Phase 2 trial for Once-Daily Compound ZN-314?", "gold_answer": "Verdict: FAITHFUL. The percentage of treatment-emergent adverse events in ZN-314 participants was 38% as stated in the source.", "model_answer": "Verdict: FAITHFUL\nThe percentage of treatment-emergent adverse events in participants assigned to ZN-314 50 mg once daily in the Phase 2 trial for Once-Daily Compound ZN-314 was 38%.", "question_profile": {"topic": "life_science", "reasoning_type": "retrieval", "difficulty": 5, "task_type": "claim_quality_check", "source_id": "sample_article", "claim_text": "", "expected_verdict": "FAITHFUL", "utility_rationale": "This question requires understanding the reported percentage of treatment-emergent adverse events specifically in participants assigned to ZN-314 in the Phase 2 trial, testing cross-sentence comprehension within the document.", "quality_risk": "none"}, "sources": [{"source_id": "sample_article.md", "title": "sample_article", "chunk_id": "0", "text": "Title: Phase 2 Trial Snapshot for Once-Daily Compound ZN-314\nThe randomized, double-blind trial enrolled 180 adults with moderate inflammatory disease activity.\nParticipants were assigned in a 2:1 ratio to ZN-314 50 mg once daily or placebo for 12 weeks.\nThe primary endpoint was change in composite symptom score from baseline to week 12.\nAt week 12, mean symptom score improved by 7.8 points in the ZN-314 group and 3.1 points in placebo.\nThe between-group difference was -4.7 points (95% CI, -6.2 to -3.1; p < 0.001).\nA prespecified subgroup with baseline CRP above 10 mg/L showed a larger mean improvement of 9.1 points on ZN-314.\nTreatment-emergent adverse events occurred in 38% of ZN-314 participants and 33% of placebo participants.\nThe most common events in ZN-314 were mild nausea (11%) and transient headache (9%).\nNo treatment-related serious adverse events were reported.\nA pharmacokinetic substudy found median Tmax of 2.5 hours and apparent terminal half-life of 18 hours.\nSteady state was reached by day 5 with an accumulation ratio of 1.4.\nFood delayed Tmax by roughly 1 hour but did not materially change AUC."}], "novelty": {"method": "llm", "max_similarity": 0.5862, "verdict": {"is_novel": true, "confidence": 1, "rationale": "The candidate question is asking about the percentage of treatment-emergent adverse events in participants assigned to ZN-314 50 mg once daily in the Phase 2 trial for Once-Daily Compound ZN-314, which is different from all the previous questions that focused on participant assignment, primary endpoint, symptom score improvement, and subgroup analysis."}}, "evaluation": {"score": 1.0, "is_correct": true, "feedback": "The candidate answer is faithful as it accurately states the percentage of treatment-emergent adverse events in participants assigned to ZN-314 50 mg once daily in the Phase 2 trial for Once-Daily Compound ZN-314 as 38%, matching the information provided in the source.", "error_type": "None", "quality_flags": [], "ambiguity_note": "None", "claim_verdict_match": true}}
